Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
Novartis’ Fabhalta, UCB’s Briviact and More to Join NHI Price List on Aug. 15
The Central Social Insurance Medical Council (Chuikyo) on August 7 approved 12 medicines for reimbursement listing later this month, with the largest peak sales projected for Novartis Pharma’s Fabhalta (iptacopan), a treatment for paroxysmal nocturnal hemoglobinuria (PNH). Fabhalta is expected…
To read the full story
Related Article
- Haihe Steps into Japan Oncology Space as CEO Sees Growth Potential
January 10, 2025
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Haihe’s MET Inhibitor Haiyitan Set for Launch on Oct. 11
September 25, 2024
- UCB’s Anti-Epileptic Drug Briviact Now Available in Japan
September 2, 2024
- Takeda Rolls Out CMV Drug Livtencity in Japan
August 29, 2024
- GSK Introduces Asthma Drug Relvar for Children in Japan
August 26, 2024
- Lilly’s BTK Inhibitor Jaypirca Hits Japan Market for MCL
August 22, 2024
- Fabhalta, Omjjara, Avigan Now Available in Japan
August 19, 2024
REGULATORY
- Japan Panel to Weigh Keytruda SC, J&J Psoriasis Pill among 6 NMEs on Aug. 24
August 18, 2026
- PMDA Urges Quality-Driven Biosimilar Development as CES Waivers Take Hold
August 18, 2026
- Japan Calls for APOE Testing before Leqembi, Kisunla Treatment
August 18, 2026
- Label Revised for DMD Drug Viltepso Based on PIII Miss
August 18, 2026
- Trazenta Draws 8 Generic Entrants as Japan Clears New DPP-4 Copies
August 17, 2026
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…